.png)
SummaryOn Friday, 12 June 2026, the Bundestag debated the GKV-Beitragssatzstabilisierungsgesetz for the first time.1 In our first article we explained the three new instruments that are set to fundamentally change the patent market. That statutory measures to stabilise GKV finances will come is regarded as politically likely; what remains open is the form in which the proposed instruments are adopted. This article orders who says what and what it means concretely for the three patent-market instruments. It is written for professionals, not patients.
Rarely has a bill provoked so many public reactions in advance. The pharmaceutical industry, health insurance funds, the Bundesrat and medical associations have taken clear, in part diametrically opposed positions.
Federal Health Minister Nina Warken (CDU) defended the act firmly, arguing that revenue and expenditure in the GKV must be brought into balance and that without countermeasures a funding gap of 44 billion euro would arise by 2040; the aim was to prevent contribution-rate rises and create planning certainty for companies.14 The opposition pushed back: Ates Gürpinar (Die Linke) called the act a chainsaw reform that mows down existing structures, and other groups criticised that it would not suffice to prevent further contribution rises.14
| Instrument | What it means | From when |
|---|---|---|
| Dynamic manufacturer discount | Additional discount on top of the existing 7% discount. Height depends on GKV expenditure trends, not plannable. | 1 Jan 2027 (3.5% static), annually dynamic from 1 Jul 2027 |
| Section 130e: patent-market rebate contracts | Funds may, for the first time, tender therapeutically comparable patent-protected active ingredients against one another. 5 pilot groups. | Expected on entry into force |
| Tightened price moratorium | Price reference: in future the lowest market price of any supplier, no longer the manufacturer's own historical price. | 1 Jan 2027 |
| Instrument | Industry | Health insurance funds | Bundesrat / G-BA / physicians |
|---|---|---|---|
| Dynamic discount | Strictly opposed, constitutional challenge possible | Necessary and proportionate | Bundesrat: deletion recommended | G-BA: raise, but not automatically |
| Section 130e rebate contracts | A fundamental break with the system | Savings potential exists | KBV: encroachment on freedom of therapy | G-BA: fiscally comprehensible, implementation hard |
| Price moratorium | Competitive distortion, launch risk | Welcomed (corrects circumvention) | Barely addressed |
| Market participant | Potential effect (per government bill) | Main instrument |
|---|---|---|
| Patent manufacturers | Heavily burdened, combined discounts, price competition despite patent | All three |
| Generic manufacturers | Burdened, launch timing decisive | Price moratorium |
| Health insurance funds | Savings expected, new tender competence | Section 130e + discount |
| Pharmacies | Neutral to slightly burdened, more dispensing complexity | Section 130e |
| Wholesale | Shortage and inventory-value risk on tender awards | Section 130e |
What the industry says. The rejection is cross-sector and unusually loud. The chair of the German pharmaceutical industry association BPI, Oliver Kirst, called the bill one full of risks and dangers and the dynamic discount a penalty on innovation, arguing that patenting a molecule today takes another twelve to fifteen years on average before it reaches the market, and that such investments cannot be justified with constantly changing price tags.3 According to the vfa and the chemical-industry association VCI, the mechanism makes companies liable for developments they can neither steer nor calculate, the economy, wage trends, demographics and prescribing behaviour across the whole market.4 Pharma Deutschland presented a commissioned legal opinion finding that central elements of the BStabG could, with high probability, breach Article 12(1) of the Basic Law.5
The vfa published concrete simulation figures: under the assumptions in the bill, the dynamic manufacturer discounts could reach 10.5% (2027), 13% (2028), 16% (2029) and 20% (2030),12 a fivefold increase by 2030, and combined with section 130e rebate contracts the prices of individual medicines could fall by up to 50% and more.12 A model calculation cited by the industry illustrates the long-term effect: a molecule patented today could face a total discount of up to 31.8% on market entry in ten years,6 against 7% today. BPI adds a dimension barely discussed so far: the United States pursues a most-favoured-nation principle that could use low prices in Germany as an international reference, raising the risk that price pressure in Germany works far beyond the domestic market through international referencing.3,7
What the ministry says. The Federal Ministry of Health rejects the criticism, arguing that the dynamic discount achieves a sustainable contribution limited to the necessary extent, with generics, biosimilars and supply-critical medicines exempt and special rules foreseen for investment in clinical trials or production sites in Germany.8
What the funds say. Ulrike Elsner, chair of the association of substitute funds (vdek), does not find the industry's warnings credible, pointing out that GKV spending on medicines has more than doubled in fifteen years and reached a record 60 billion euro in 2025, while the industry records record profits, and that politics must not cave in to such threats.9
What the Bundesrat says. The Bundesrat committees had already adopted almost 50 recommendations in late May, including a recommendation to delete the dynamic manufacturer discount.10
What the G-BA says. On 17 June the impartial members of the Federal Joint Committee (G-BA) submitted a differentiated statement.15 They consider a clear increase of the manufacturer discount appropriate and warranted, but warn of undesirable effects of an automatic dynamisation not steerable by correction factors, for example in years when several high-priced first-in-class substances are newly approved. Their concrete proposal: raise the discount to 13 percent and, instead of automatic dynamisation, provide by law for a review and adjustment every three years taking special effects into account.15 That is a robust compromise from a body representing neither industry nor fund interests.
What the industry says. The legal opinion commissioned by Pharma Deutschland calls the cluster tenders under section 130e a fundamental break with the system in the handling of patent-protected medicines,5 seeing a double regulation: the added benefit is assessed under the AMNOG but effectively devalued by cluster tenders, because in the end the highest rebate decides market access. vfa president Han Steutel argues the tenders would replace innovation competition for the best therapy with price-driven prescribing control, threatening patients with fewer therapy options and more frequent switches.4 The National Association of Statutory Health Insurance Physicians (KBV) criticises section 130e from another angle: by coupling the tenders to the efficiency review and planned prescribing quotas, contract physicians would effectively be pushed to prescribe the tender winner, an encroachment on physicians' freedom of therapy.11
Assessment. The five substance groups are named concretely in the bill.13 That group formation lies with the funds, not the G-BA, is seen by many participants as one of the most politically vulnerable elements. The impartial G-BA members themselves consider the fiscal approach broadly comprehensible but warn of implementation difficulties in defining therapeutic comparability, and propose additionally enabling the G-BA to form reference-price groups for patent-protected medicines too.15 For manufacturers in these five groups, the preparation time is now, regardless of the outcome.
The tightened price moratorium is the least publicly discussed of the three instruments, but for generic manufacturers and late market entrants one of the most consequential. The new rule ties the price reference no longer to the manufacturer's own historical price but to the lowest market price of any supplier of the same active ingredient.13 This could mean that early market entries after patent expiry have a stronger influence on later price references. Whoever comes too late loses not only market share but also pricing flexibility.
The parliamentary procedure is still open, but the core questions for manufacturers and market-access teams have sharpened: which products fall under the dynamic discount and which under exemptions (a classification to prepare now in the IFA data); whether own products sit in one of the five section 130e pilot groups, given that the funds' tender preparation realistically takes several months after entry into force; and which active-ingredient price is already set at the planned market entry, making the first notification date after patent expiry a strategic target. The underlying pricing data is set out in our overview of pharmaceutical pricing and market access in Germany.
Pharmaceutical wholesale faces concentration of demand on the tender winner, creating shortage and inventory-value risks for stock held at old purchase prices; a real-time view of reported shortages, such as a drug shortage database for Germany, supports early warning. Pharmacies may face exclusive award contracts for patent-protected active ingredients under section 130e alongside existing generic rebate contracts and the section 40c biosimilar substitution duty, requiring a current rebate-contract overview and shortage information. Health insurance funds hold section 130e in force with the act, with group formation, equivalence assessment and tender design resting entirely with them and realistically several months of legal preparation ahead.
The parliamentary procedure enters its decisive phase. Whether and how strongly the three patent-market instruments are softened is decided by the public hearing and the committee deliberations before 26 June. pharmazie.com keeps professionals current with IFA data, price history, an AMNOG database and a shortage overview in one platform, exclusively for healthcare professionals.
1 Deutscher Bundestag: Stabilisierung der Beitragssätze in der gesetzlichen Krankenversicherung, first reading, 12 June 2026. bundestag.de
6 Model calculation on the dynamic manufacturer discount, pharma-fakten.de. pharma-fakten.de
7 vfa: the BStabG threatens innovation, supply and location (MFN dimension). vfa.de
8 Pharmazeutische Zeitung: the ministry defends the dynamic manufacturer discount. pharmazeutische-zeitung.de
13 Bundesregierung: government bill GKV-Beitragssatzstabilisierungsgesetz (BStabG), Drucksache 21/6130. dserver.bundestag.de
15 Gemeinsamer Bundesausschuss (G-BA): statement of the impartial members on the BStabG (Drs. 21/6130), 17 June 2026. g-ba.de
Further sources (statements and reporting): BPI (Deutsches Ärzteblatt, 11 June 2026); vfa/VCI location-policy warning; Pharma Deutschland constitutional opinion (Möhrle Happ Luther); vdek statement of 12 June 2026; Deutsches Ärzteblatt on the Bundesrat, 12 June 2026; KBV statement of 20 April 2026; vfa BStabG fact sheet (May 2026); Apotheke Adhoc, 12 June 2026.
